<DOC>
	<DOCNO>NCT02849132</DOCNO>
	<brief_summary>Patients complete 2-years entecavir-based treatment Regress Study receive another 5-years entecavir extension therapy . Patients assessed baseline every six month blood cell count , liver function test , HBVDNA , AFP , prothrombin time , liver ultrasonography , Fibroscan ; A third liver biopsy perform year 3 patient significant fibrosis second biopsy . CT endoscopy perform baseline year 3 .</brief_summary>
	<brief_title>Effect Entecavir Treatment Regression Disease Outcome HBV-induced Liver Fibrosis Cirrhosis Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>Subjects complete 2 year entecavirbased therapy Regress study ; Subjects willing participate extension study . Any complication severe heart , lung , kidney , brain , blood disease important systematic disease ; Pregnant woman ; Subjects could compliance protocol judge investigator ; Subjects suitable study judge investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>